{"id":"W4401526042","doi":"10.1093/rheumatology/keae432","title":"A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment","year":2024,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; Gilead Sciences; AbbVie; Sanofi; Amgen; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Secukinumab; Medicine; Ankylosing spondylitis; Spondylitis; Disease; Internal medicine; Gastroenterology; Surgery; Psoriatic arthritis","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001710554,0.0007881472,0.001987154,0.0002775034,0.0002542994,0.0005810565,0.0004793222,0.0007326517,0.002241649],"category_scores_gemma":[0.0009858345,0.0004303218,0.0009554155,0.0003366887,0.0004176306,0.0005596835,0.0002477744,0.001505621,0.0004721813],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004009878,"about_ca_system_score_gemma":0.0005659714,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003061978,"about_ca_topic_score_gemma":0.0008829281,"domain_scores_codex":[0.999337,0.0003646547,0.00005224291,0.00008422101,0.00007632156,0.00008547308],"domain_scores_gemma":[0.9993162,0.0001172661,0.0002142168,0.00007067948,0.0000493879,0.0002322606],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8493655,0.02978743,0.01729361,0.0008383431,0.001778787,0.0002017817,0.0002783092,0.001188613,0.02534862,0.0001110889,0.001091614,0.07271637],"study_design_scores_gemma":[0.4851692,0.4547674,0.05505008,0.00004280998,0.0006516437,0.0002045537,0.00005536283,0.001048828,0.00138801,0.00008330664,0.001512047,0.00002673934],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977597,0.001114817,0.0001083054,0.0001050563,0.00003969335,0.0003232371,0.0001303535,0.00001963364,0.0003990477],"genre_scores_gemma":[0.997475,0.0005493926,0.0003467642,0.0002454715,0.0000560355,0.0004714207,0.0002787025,0.000004319613,0.0005729373],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002241649,"threshold_uncertainty_score":0.009046376,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01065696882606191,"score_gpt":0.2614228264870171,"score_spread":0.2507658576609552,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}